Results 121 to 130 of about 7,486 (163)

Longitudinal and Stability-Aware Analysis Reveals Treatment-Specific MicroRNA Response Signatures Following Immune-Reconstitution and B-Cell-Targeted Therapies in Multiple Sclerosis. [PDF]

Int J Mol Sci
Ata N, Mytych JS, Cerghet M, Rattan R, Govil S, Giri S, Mao-Draayer Y.   +6 more
europepmc   +1 more source

Early Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis. [PDF]

Neurol Ther
Alvarez E, Naismith RT, Hua LH, Pineda ED, Romdhani H, Guérin A, Lévesque-Leroux M, Marathe G, Nakamura K, Ontaneda D.   +9 more
europepmc   +1 more source

Network meta-analysis of triple immunosuppressive therapies and standard of care for induction of remission of active lupus nephritis. [PDF]

Lupus
Contreras G, Mechery V, Kota S, Del Castillo Rix D, Bandes M, Dejman A, Zuo Y, Duque JC, Munoz Mendoza J.   +8 more
europepmc   +1 more source

Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity. [PDF]

J Neurol Neurosurg Psychiatry
Konen FF, Axhausen F, Wolff S, Mühlenbrock P, Gingele S, Jendretzky KF, Nay S, Grote-Levi LM, Schwenkenbecher P, Meuth SG, Skripuletz T, Pfeuffer S.   +11 more
europepmc   +1 more source

Ocrelizumab-Induced Brain Volume Dynamics in Relapsing-Remitting Multiple Sclerosis. [PDF]

Pharmaceuticals (Basel)
De Masi R, Orlando S.
europepmc   +1 more source

<i>FCGR3A</i> Polymorphism Controls B-Cell Repopulation Kinetics in People With Multiple Sclerosis Treated With Ocrelizumab. [PDF]

Neurol Neuroimmunol Neuroinflamm
Abbadessa G, Chianese U, Russo C, Miele G, Maida E, Esposito G, Romano G, Bile F, Signoriello E, Lus G, Lavorgna L, Nicholas RS, Altucci L, Procaccini C, Matarese G, Benedetti R, Bonavita S.   +16 more
europepmc   +1 more source

The Effect of Ocrelizumab on Anti-JC Virus Antibody Index. [PDF]

Brain Behav
Virupakshaiah A, Gill AJ, Schoeps VA, Wilson E, Wilson J, Do D, Bar-Or A, Jacobs D, Berger JR.   +8 more
europepmc   +1 more source

Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial. [PDF]

Eur J Neurol
Vermersch P, Benedict RHB, Van Wijmeersch B, Cutter G, Kister L, Oreja-Guevara C, Siva A, Wiendl H, Wuerfel J, El Azzouzi B, Kuenzel T, Buffels R, Craveiro L, Dirks P, Comi G.   +14 more
europepmc   +1 more source

Personalised Anti-CD20 Retreatment in Multiple Sclerosis: Precision Medicine or Precision Pharmacology? [PDF]

Eur J Neurol
Schmierer K.
europepmc   +1 more source

Real-world pharmacovigilance analysis of the association between multiple sclerosis disease-modifying therapies and intervertebral disc herniation. [PDF]

Front Pharmacol
Yang N, Liu H, Zhou Y, Feng H.
europepmc   +1 more source